ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis

Company Overview

ANI Pharmaceuticals, Inc. is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care. Alongside its proprietary generics business, ANI provides contract development and manufacturing organization (CDMO) services, leveraging its integrated in-house capabilities in sterile and nonsterile production, analytical testing and regulatory support to meet the needs of pharmaceutical partners.

Primarily serving markets in North America, ANI maintains multiple U.S. manufacturing facilities certified for complex sterile and nonsterile operations. The company collaborates with major distributors, retail pharmacies, hospitals and healthcare systems, and continues to invest in process optimization and quality systems to expand its product pipeline and support evolving patient needs.

Key Stats

• Today's Range: $94.80 to $96.35
• 50-Day Range: $63.35 to $94.92
• 52-Week Range: $52.50 to $96.35
• Volume: 246,182 shs
• Average Volume: 374,451 shs
• Market Capitalization: $2.09 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $84.75
• Consensus Rating: Buy

ANI Pharmaceuticals Stock Analysis - MarketRank™

ANI Pharmaceuticals scored higher than 74% of companies evaluated by MarketBeat, and ranked 275th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.6 / 5
• Analyst Rating: Buy

Consensus Rating

ANI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.10, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

ANI Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 9.07%

Earnings Growth

Earnings for ANI Pharmaceuticals are expected to grow by 9.07% in the coming year, from $3.86 to $4.21 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ANI Pharmaceuticals is -124.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ANI Pharmaceuticals is -124.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ANI Pharmaceuticals has a P/B Ratio of 4.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.14% of the outstanding shares of ANI Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

ANI Pharmaceuticals has a short interest ratio ("days to cover") of 5.

Change versus previous month

Short interest in ANI Pharmaceuticals has recently decreased by 0.45%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ANI Pharmaceuticals does not currently pay a dividend.

Dividend Growth

ANI Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.3 / 5
• Environmental Score: -2.48

Percentage of Shares Shorted

10.14% of the outstanding shares of ANI Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

ANI Pharmaceuticals has a short interest ratio ("days to cover") of 5.

Change versus previous month

Short interest in ANI Pharmaceuticals has recently decreased by 0.45%, indicating that investor sentiment is improving.

News and Social Media

• Score: 4.1 / 5
• News Sentiment: 1.34

News Sentiment

ANI Pharmaceuticals has a news sentiment score of 1.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for ANI Pharmaceuticals this week, compared to 7 articles on an average week.

Search Interest

13 people have searched for ANIP on MarketBeat in the last 30 days. This is an increase of 550% compared to the previous 30 days.

MarketBeat Follows

3 people have added ANI Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, ANI Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $35,690,131.00 in company stock.

Percentage Held by Insiders

12.70% of the stock of ANI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

76.05% of the stock of ANI Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ANIP Stock Analysis - Frequently Asked Questions

How have ANIP shares performed this year?

ANI Pharmaceuticals' stock was trading at $55.28 at the beginning of 2025. Since then, ANIP stock has increased by 74.0% and is now trading at $96.1950.

How were ANI Pharmaceuticals' earnings last quarter?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) issued its quarterly earnings data on Friday, August, 8th. The specialty pharmaceutical company reported $1.80 EPS for the quarter, beating analysts' consensus estimates of $1.42 by $0.38. ANI Pharmaceuticals's revenue for the quarter was up 53.2% on a year-over-year basis.
Read the conference call transcript.

Who are ANI Pharmaceuticals' major shareholders?

Top institutional investors of ANI Pharmaceuticals include Global Alpha Capital Management Ltd. (3.98%), Ranger Investment Management L.P. (2.46%), William Blair Investment Management LLC (2.26%) and Geode Capital Management LLC (1.97%). Insiders that own company stock include Meridian Venture Partners Ii L, Muthusamy Shanmugam, Nikhil Lalwani, Stephen P Carey, Chad Gassert, James G Marken, Christopher Mutz, Ori Gutwerg, Meredith Cook, Patrick D Walsh, Krista Davis, Thomas Andrew Rowland, Thomas Haughey, Antonio R Pera, Jeanne Thoma, Renee P Tannenbaum and Matthew J Leonard.
View institutional ownership trends.

How do I buy shares of ANI Pharmaceuticals?

Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ANI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ANI Pharmaceuticals investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 8/08/2025
• Today: 9/04/2025
• Next Earnings (Estimated): 11/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ANIP
• Previous Symbol: NASDAQ:BPAX
• CIK: 1023024
• Web: www.anipharmaceuticals.com
• Phone: (218) 634-3500
• Fax: 218-634-3540
• Employees: 600
• Year Founded: 1996

Price Target and Rating

• Average Price Target for ANI Pharmaceuticals: $84.75
• High Price Target: $94.00
• Low Price Target: $77.00
• Potential Upside/Downside: -10.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.10
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.77)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 24.59
• P/E Growth: N/A
• Net Income: -$18.52 million
• Net Margins: -1.37%
• Pretax Margin: -1.97%
• Return on Equity: 25.03%
• Return on Assets: 8.00%

Debt

• Debt-to-Equity Ratio: 1.39
• Current Ratio: 2.54
• Quick Ratio: 1.96

Sales & Book Value

• Annual Sales: $614.38 million
• Price / Sales: 3.35
• Cash Flow: $7.71 per share
• Price / Cash Flow: 12.31
• Book Value: $20.13 per share
• Price / Book: 4.72

Miscellaneous

• Outstanding Shares: 21,700,000
• Free Float: 18,944,000
• Market Cap: $2.06 billion
• Optionable: Optionable
• Beta: 0.63